Cargando…
A Novel Probiotic-Based Oral Vaccine against SARS-CoV-2 Omicron Variant B.1.1.529
COVID-19 pandemic, caused by the SARS-CoV-2 virus, is still affecting the entire world via the rapid emergence of new contagious variants. Vaccination remains the most effective prevention strategy for viral infection, yet not all countries have sufficient access to vaccines due to limitations in ma...
Autores principales: | Chau, Eddie Chung Ting, Kwong, Tsz Ching, Pang, Chun Keung, Chan, Lee Tung, Chan, Andrew Man Lok, Yao, Xiaoqiang, Tam, John Siu Lun, Chan, Shun Wan, Leung, George Pak Heng, Tai, William Chi Shing, Kwan, Yiu Wa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10530581/ https://www.ncbi.nlm.nih.gov/pubmed/37762235 http://dx.doi.org/10.3390/ijms241813931 |
Ejemplares similares
-
Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance
por: Chen, Jiahui, et al.
Publicado: (2021) -
The rapid replacement of the Delta variant by Omicron (B.1.1.529) in England
por: Paton, Robert S., et al.
Publicado: (2022) -
Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron)
por: Grüne, Barbara, et al.
Publicado: (2022) -
Identifying susceptibility of children and adolescents to the Omicron variant (B.1.1.529)
por: Chun, June Young, et al.
Publicado: (2022) -
Omicron B.1.1.529 subvariant: Brief evidence and future prospects
por: Farahat, Ramadan Abdelmoez, et al.
Publicado: (2022)